Table 2. Disease details and outcomes at diagnosis of SJS, stratified by AKI Status.
| Variable | All patients | AKI | Non-AKI | P value |
|---|---|---|---|---|
| Disease type, n (%) | 0.007 | |||
| SJS | 56 (74.7) | 12 (52.2) | 44 (84.6) | |
| TEN | 16 (21.3) | 9 (39.1) | 7 (13.5) | |
| Overlap syndrome | 3 (4.0) | 2 (8.7) | 1 (1.9) | |
| Drug, n (%) | 0.234 | |||
| Allopurinol | 24 (32.0) | 10 (43.5) | 14 (26.9) | |
| Phenytoin | 10 (13.3) | 3 (13.0) | 7 (13.5) | |
| Carbamazepine | 6 (8.0) | 0 (0) | 6 (11.5) | |
| Trimethoprim-sulfamethoxazole | 3 (4.0) | 1 (4.3) | 2 (3.8) | |
| NSAIDs | 1 (1.3) | 1 (4.3) | 0 (0) | |
| Others | 31 (41.3) | 8 (34.8) | 23 (44.2) | |
| Complication, n (%) | ||||
| Mechanical ventilation | 15 (20.0) | 11 (47.8) | 4 (7.7) | < 0.001 |
| Shock | 19 (25.3) | 15 (65.2) | 4 (7.7) | < 0.001 |
| Bloodstream infection | 8 (10.7) | 6 (26.1) | 2 (3.8) | 0.009 |
| Intensive care unit admission | 23 (30.7) | 15 (65.2) | 8 (15.4) | < 0.001 |
| Hemodialysis | 14 (18.7) | 14 (60.9) | 0 (0) | < 0.001 |
| Outcome, n (%) | ||||
| Hospital days | 13 (11) | 18 (28) | 11 (8) | 0.012 |
| In-hospital mortality | 15 (20.0) | 13 (56.5) | 2 (3.8) | < 0.001 |
| 1-year mortality | 19 (25.3) | 16 (69.6) | 3 (5.8) | < 0.001 |
Continuous data are presented as median (interquartile range).
AKI, acute kidney injury; DRESS, drug reaction with eosinophilia and systemic symptoms; NSAIDs, nonsteroidal anti-inflammatory drugs; SJS, Stevens–Johnson syndrome; TEN, toxic epidermal necrolysis.